NIH scientists develop candidate vaccine against respiratory syncytial virus

Thursday, October 31, 2013

Structure-based design may be key to successful vaccine for common childhood illness

An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.